{"id":"NCT03120949","sponsor":"R-Pharm International, LLC","briefTitle":"Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis","officialTitle":"A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-07-04","primaryCompletion":"2021-09-01","completion":"2021-09-01","firstPosted":"2017-04-19","resultsPosted":"2022-06-07","lastUpdate":"2023-10-12"},"enrollment":2106,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Olokizumab 64 mg SC q4w","otherNames":[]},{"type":"DRUG","name":"Olokizumab 64 mg SC q2w","otherNames":[]},{"type":"DRUG","name":"Concomitant treatment","otherNames":[]}],"arms":[{"label":"Treatment Arm 1: OKZ 64 mg q4w + MTX","type":"EXPERIMENTAL"},{"label":"Treatment Arm 2: OKZ 64 mg q2w + MTX","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study was to evaluate the long-term safety and tolerability of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) in subjects with moderately to severely active rheumatoid arthritis (RA) who previously had completed 24 weeks of double-blind treatment in Study CREDO 1, 2 or 3 (core studies). The long-term efficacy, immunogenicity, the physical function and quality of life of subjects received long-term treatment with OKZ were assessed as well.","primaryOutcome":{"measure":"Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population)","timeFrame":"up to Week 126","effectByArm":[{"arm":"Treatment Arm 1: OKZ 64 mg q4w + MTX","deltaMin":401,"sd":null},{"arm":"Treatment Arm 2: OKZ 64 mg q2w + MTX","deltaMin":408,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":239,"countries":["United States","Argentina","Belarus","Brazil","Bulgaria","Colombia","Czechia","Estonia","Germany","Hungary","Latvia","Lithuania","Mexico","Poland","Russia","South Korea","Taiwan","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":129,"n":1043},"commonTop":["Alanine aminotransferase increased","Nasopharyngitis","Upper respiratory tract infection","Aspartate aminotransferase increased","Leukopenia"]}}